Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerold Bepler

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Pancreas|October 18, 2016
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway ApproachJames J Farrell, Jennifer Moughan, Jonathan L Wong, et al.
Cancer Immunology, Immunotherapy : CII|December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancerAlberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2010
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancerAlberto Chiappori, Gerold Bepler, Fabrice Barlesi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
The guinea pig syndrome: improving clinical trial participation among thoracic patientsGwendolyn P Quinn, Bethany A Bell, Miriam Y Bell, et al.
Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II studyRonald Natale, Fiona Blackhall, Dariusz Kowalski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancerGerold Bepler, Charles Williams, Michael J Schell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2014
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumorsJhanelle E Gray, Eric Haura, Alberto Chiappori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
Cancer|October 20, 2011
Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assayValsamo K Anagnostou, Anastasios T Dimou, Taxiarchis Botsis, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Pancreas|October 18, 2016
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway ApproachJames J Farrell, Jennifer Moughan, Jonathan L Wong, et al.
Cancer Immunology, Immunotherapy : CII|December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancerAlberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2010
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancerAlberto Chiappori, Gerold Bepler, Fabrice Barlesi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
The guinea pig syndrome: improving clinical trial participation among thoracic patientsGwendolyn P Quinn, Bethany A Bell, Miriam Y Bell, et al.
Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II studyRonald Natale, Fiona Blackhall, Dariusz Kowalski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancerGerold Bepler, Charles Williams, Michael J Schell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2014
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumorsJhanelle E Gray, Eric Haura, Alberto Chiappori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
Cancer|October 20, 2011
Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assayValsamo K Anagnostou, Anastasios T Dimou, Taxiarchis Botsis, et al.
Pageof 16